AU2007233123A1 - Linear natriuretic peptide constructs - Google Patents

Linear natriuretic peptide constructs Download PDF

Info

Publication number
AU2007233123A1
AU2007233123A1 AU2007233123A AU2007233123A AU2007233123A1 AU 2007233123 A1 AU2007233123 A1 AU 2007233123A1 AU 2007233123 A AU2007233123 A AU 2007233123A AU 2007233123 A AU2007233123 A AU 2007233123A AU 2007233123 A1 AU2007233123 A1 AU 2007233123A1
Authority
AU
Australia
Prior art keywords
amino acid
aaa
construct
ala
surrogate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007233123A
Other languages
English (en)
Inventor
Margarita Bastos
Hui-Zhi Cai
Shubh D. Sharma
Wei Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palatin Technologies Inc
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of AU2007233123A1 publication Critical patent/AU2007233123A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007233123A 2006-03-30 2007-03-30 Linear natriuretic peptide constructs Abandoned AU2007233123A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74396306P 2006-03-30 2006-03-30
US74396406P 2006-03-30 2006-03-30
US60/743,964 2006-03-30
US60/743,963 2006-03-30
PCT/US2007/065656 WO2007115182A2 (en) 2006-03-30 2007-03-30 Linear natriuretic peptide constructs

Publications (1)

Publication Number Publication Date
AU2007233123A1 true AU2007233123A1 (en) 2007-10-11

Family

ID=38564250

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007233123A Abandoned AU2007233123A1 (en) 2006-03-30 2007-03-30 Linear natriuretic peptide constructs

Country Status (6)

Country Link
US (1) US7795221B2 (enExample)
EP (1) EP2004633A4 (enExample)
JP (1) JP2009532385A (enExample)
AU (1) AU2007233123A1 (enExample)
CA (1) CA2647146A1 (enExample)
WO (1) WO2007115182A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795221B2 (en) 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
US8114844B2 (en) 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
US7964181B2 (en) * 2006-03-30 2011-06-21 Palatin Technologies, Inc. Amino acid surrogates for peptidic constructs
MX2008012649A (es) * 2006-03-30 2008-10-13 Palatin Technologies Inc Sustitutos de aminoacido para constructos peptidicos.
EP2001518B1 (en) 2006-03-30 2013-07-10 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
IL186004A0 (en) * 2007-09-17 2008-01-20 Ariel University Res And Dev C Piperzine-based scaffolds for solid phase synthesis of combinatorial libraries and method for their preparation
WO2011005939A2 (en) 2009-07-09 2011-01-13 Mayo Foundation For Medical Education And Research Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
UY32902A (es) 2009-09-25 2011-02-28 Alcon Res Ltd Nuevos agonistas de npr-b
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
CN103906761B (zh) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 利钠多肽
WO2013062900A1 (en) * 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2771005B1 (en) * 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US20140066367A1 (en) * 2012-08-31 2014-03-06 Mayo Foundation For Medical Education And Research Subcutaneous delivery of a long-acting natriuretic peptide
EP3119448B1 (en) 2014-03-21 2020-04-22 University of Pittsburgh- Of the Commonwealth System of Higher Education Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix
WO2015175502A2 (en) * 2014-05-12 2015-11-19 Palatin Technologies, Inc. Replacement therapy for natriuretic peptide deficiencies
AU2017207015B2 (en) 2016-01-13 2022-08-04 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Vascular extracellular matrix hydrogel
EP3983437A1 (en) 2019-06-12 2022-04-20 Novartis AG Natriuretic peptide receptor 1 antibodies and methods of use
WO2025054172A1 (en) 2023-09-05 2025-03-13 E-Star Biotech, LLC Formulations of manp and uses thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US465158A (en) * 1891-12-15 Charles m
US4251438A (en) 1979-06-14 1981-02-17 The Upjohn Company Piperazinone and piperazine polypeptides
US4341698A (en) * 1979-06-21 1982-07-27 Richardson-Merrell Inc. Enkaphalin derivatives
US4496544A (en) 1983-11-10 1985-01-29 Washington University Atrial Peptides
US4952561A (en) 1984-02-07 1990-08-28 Merck & Co., Inc. Cardiac atrial peptides
JPS60184098A (ja) 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US4618600A (en) 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
US5212286A (en) 1984-04-19 1993-05-18 Scios Nova Inc. Atrial natriuretic/vasodilator peptide compounds
JPH0780907B2 (ja) 1984-04-19 1995-08-30 シオス・ノバ・インク 新規な心房性ナトリウム尿排泄亢進性及び血管拡張性ポリペプチド
WO1985004872A1 (en) 1984-04-24 1985-11-07 The Salk Institute For Biological Studies Atrial peptide analogs
JPH0672155B2 (ja) 1984-08-24 1994-09-14 塩野義製薬株式会社 α−ｈＡＮＰ抗血清作製用ポリペプチド
US4609725A (en) 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
IE862891L (en) * 1985-11-05 1987-05-05 Behringwerke Ag Analogs of atrial natriuretic peptides
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
DE3614833A1 (de) 1986-01-16 1987-07-23 Hoechst Ag Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5057603A (en) 1986-01-31 1991-10-15 Merck & Co., Inc. Peptides having ANF activity
US4716147A (en) 1986-03-27 1987-12-29 Monsanto Company Synthetic airial peptides
EP0246795A3 (en) 1986-05-20 1990-04-04 Advanced Peptide Development Limited Synthetic natriuretic peptides
US5159061A (en) 1986-09-29 1992-10-27 Takeda Chemical Industries, Ltd. Atrial natriuretic peptide derivative
US4804650A (en) 1986-10-28 1989-02-14 Biotechnology Research Associates, J.V. Analogs of atrial natriuretic peptides
DK531986D0 (da) 1986-11-07 1986-11-07 Novo Industri As Peptider
DE3878231T2 (de) 1987-03-02 1993-05-27 Bissendorf Peptide Gmbh Neues cadiodilatin-fragment, prozess zu dessen herstellung und dessen anwendung.
US5095004A (en) 1987-03-25 1992-03-10 Bio-Mega Inc. Fluorine containing atrial natriuretic peptides
US5376635A (en) 1987-03-15 1994-12-27 Bio-Mega/Boehringer Ingelheim Research Inc. Fluorine containing atrial natriuretic peptides
US5091366A (en) 1987-05-19 1992-02-25 Merck & Co., Inc. Peptides having ANF activity
US4816443A (en) 1987-05-19 1989-03-28 Merck & Co., Inc. Piptides having ANF activity
IL86386A0 (en) 1987-05-21 1988-11-15 Merrell Dow Pharma Novel anf derivatives
JP2544929B2 (ja) 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
JP2855143B2 (ja) 1987-12-24 1999-02-10 サイオス インコーポレイテッド 心房の，ナトリウム排出亢進性ペプチドの直鎖アナログ
US4935492A (en) 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
US5047397A (en) 1988-08-26 1991-09-10 California Biotechnology Inc. Linear analogs of atrial natriuretic peptides
EP0341603A3 (en) 1988-05-09 1990-07-04 Abbott Laboratories Atrial peptide derivatives
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5057495A (en) 1988-06-24 1991-10-15 Queen's University At Kingston Atrial hypotensive peptide
DK380288D0 (da) 1988-07-07 1988-07-07 Novo Industri As Hidtil ukendet peptider
AU4211989A (en) 1988-08-18 1990-03-23 California Biotechnology, Inc. Atrial natriuretic peptide clearance inhibitors
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5106834A (en) * 1988-12-27 1992-04-21 G. D. Searle & Co. Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents
EP0385476B2 (en) 1989-03-01 1999-09-22 SHIONOGI & CO., LTD. Physiologically active polypeptide and DNA
CA2033198A1 (en) 1989-05-24 1990-11-25 Scott D. Lucas Atrial peptide derivatives
CA2059131A1 (en) 1989-06-23 1990-12-24 Ming-Shi Chang Compositions and methods for the synthesis of natriuretic protein receptor b and methods of use
ATE164080T1 (de) 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
JPH06501950A (ja) 1990-10-11 1994-03-03 ベーリンガー　インゲルハイム　コマンディトゲゼルシャフト 環状ペプチド、その調製法およびその薬理組成物としての使用
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US5190922A (en) 1991-06-04 1993-03-02 Abbott Laboratories Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands
JP2925391B2 (ja) 1992-01-09 1999-07-28 サントリー株式会社 Ａｒｄｓ治療用医薬組成物
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
WO1994020534A1 (en) 1993-03-03 1994-09-15 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5665704A (en) 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
DK0728147T3 (da) 1993-11-12 2003-06-10 Genentech Inc Receptorspecifikke atrienatriuretiske peptider
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5567662A (en) 1994-02-15 1996-10-22 The Dow Chemical Company Method of making metallic carbide powders
FR2717484A1 (fr) 1994-03-16 1995-09-22 Pf Medicament Nouveaux composés pseudo-bis-peptidiques analogues de la CCK, leur procédé de préparation, leur utilisation à titre de médicament et les compositions pharmaceutiques les comprenant .
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
ZA971864B (en) 1996-03-04 1997-12-18 Scios Inc Assays and reagents for quantifying hBNP.
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
AU739469B2 (en) 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US5965533A (en) 1997-05-23 1999-10-12 Baxter International Inc. Atrial natriuretic peptide (ANP) as an additive to peritoneal dialysis solutions
US6013630A (en) 1997-08-21 2000-01-11 Curagen Corporation Atrial natriuretic factor mutants and ischemic stroke
WO1999012576A2 (en) 1997-09-11 1999-03-18 Musc Foundation For Research Development Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US6833358B1 (en) 1998-09-28 2004-12-21 Santen Pharmaceutical Co., Ltd. Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6387932B1 (en) * 1999-06-25 2002-05-14 Merck & Co., Inc. Somatostatin agonists
AU7352200A (en) 1999-09-01 2001-03-26 Regents Of The University Of California, The Novel natriuretic peptide receptors, interacting compounds and methods of regulating proliferation and/or survival of neurons
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
WO2001046291A1 (en) 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
AU2003214214A1 (en) 2002-03-18 2003-10-08 Scios Inc. Method for treating congestive heart failure
WO2003081246A1 (en) 2002-03-18 2003-10-02 Scios Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
DE60331584D1 (de) 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
AU2004215912B2 (en) 2003-02-26 2009-03-26 Nektar Therapeutics Polymer-factor VIII moiety conjugates
US20060019890A1 (en) 2004-01-15 2006-01-26 Kapoun Ann M Method for treating cardiac remodeling following myocardial injury
JP2008509746A (ja) 2004-08-11 2008-04-03 アルザ・コーポレーシヨン ナトリウム利尿ペプチドを経皮送達する器具および方法
EP2001518B1 (en) 2006-03-30 2013-07-10 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
US7795221B2 (en) 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs

Also Published As

Publication number Publication date
JP2009532385A (ja) 2009-09-10
CA2647146A1 (en) 2007-10-11
US7795221B2 (en) 2010-09-14
WO2007115182A2 (en) 2007-10-11
EP2004633A4 (en) 2009-08-26
US20070232546A1 (en) 2007-10-04
EP2004633A2 (en) 2008-12-24
WO2007115182A3 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
US7795221B2 (en) Linear natriuretic peptide constructs
AU2007233116B2 (en) Cyclic natriuretic peptide constructs
CN101505784B (zh) 环状利尿钠肽构建体
US7964181B2 (en) Amino acid surrogates for peptidic constructs
CA2647114C (en) Amino acid surrogates for peptidic constructs
US8580746B2 (en) Amide linkage cyclic natriuretic peptide constructs
US20170087205A1 (en) Replacement Therapy for Natriuretic Peptide Deficiencies
US8828926B2 (en) Uses of natriuretic peptide constructs
HK1134022B (en) Cyclic natriuretic peptide constructs

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period